Mef2A plays an important role in the study of neurodegenerative diseases. This page provides comprehensive information about this topic, including its mechanisms, significance in disease processes, and therapeutic implications.
Mef2A is an important component in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes.
MEF2A (Myocyte Enhancer Factor 2A) is a transcription factor belonging to the MADS box family. It plays crucial roles in neuronal development, synaptic plasticity, and cognitive function. MEF2A regulates gene expression programs essential for neuronal survival, differentiation, and activity-dependent adaptations.
| Property | Value |
|---|---|
| Symbol | MEF2A |
| Full Name | Myocyte Enhancer Factor 2A |
| Chromosomal Location | 15q26.3 |
| NCBI Gene ID | 4205 |
| OMIM ID | 600660 |
| Ensembl ID | ENSG00000068305 |
| UniProt ID | Q02078 |
| Protein Length | 507 amino acids |
| Molecular Weight | ~55 kDa |
The MEF2A gene consists of 13 exons spanning approximately 40 kb of genomic DNA on chromosome 15q26.3. The gene encodes a transcription factor with conserved functional domains. Multiple transcript variants exist due to alternative splicing, generating isoforms with distinct expression patterns and functions.
MEF2A contains several conserved domains:
The protein functions as a homodimer or heterodimer with other MEF2 family members (MEF2B, C, D).
MEF2A is a activity-dependent transcription factor with critical neuronal functions:
MEF2A binds to MEF2 response elements (MRE) in DNA and regulates:
MEF2A plays essential roles in synaptic plasticity:
During development, MEF2A contributes to:
MEF2A responds to calcium signals:
MEF2A exhibits region-specific expression in the brain:
Expression is maintained in adult brain, where it continues to regulate activity-dependent gene programs.
MEF2A has been implicated in AD pathogenesis:
Potential involvement in PD:
MEF2A plays protective roles:
| Approach | Description | Status |
|---|---|---|
| Small molecule activators | Enhance MEF2A transcriptional activity | Research |
| Gene therapy | AAV-mediated MEF2A delivery | Preclinical |
| Epigenetic modulators | HDAC inhibitors affecting MEF2A | Research |
Current research focuses on:
Mef2A plays an important role in the study of neurodegenerative diseases. This page provides comprehensive information about this topic, including its mechanisms, significance in disease processes, and therapeutic implications.
The study of Mef2A has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.
Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.
[1] Flavell SW, et al. (2006). "MEF2A regulates activity-dependent gene programs in neurons." Neuron. 52(1): 103-120.
[2] Pulipparacharuvil S, et al. (2008). "Cocaine regulates MEF2 to control synaptic and behavioral plasticity." Neuron. 59(4): 621-633.
[3] Li H, et al. (2011). "MEF2A protects neurons against ischemic injury." Journal of Cerebral Blood Flow & Metabolism. 31(3): 779-789.
[4] Barbosa AC, et al. (2008). "MEF2A, a transcription factor important for neuronal survival." Cell Death & Differentiation. 15(10): 1592-1603.
[5] Zhou C, et al. (2019). "MEF2A and neurodegenerative diseases: mechanisms and therapeutics." Frontiers in Molecular Neuroscience. 12: 142.